Wednesday, 14 December 2011 09:30 AM
OTTAWA, ONTARIO, December 13, 2011 - Chemaphor Inc. (TSX.V:CFR) is pleased to report that its President and Co-Founder, Dr. Graham Burton, participated in a webinar presentation to the Richmond Club. The Richmond Club, based in downtown Toronto, Ontario is an accredited investor community consisting of over 11,000 investment advisors, fund managers, accredited investors, analysts and members of the media that has a mandate for showcasing undervalued stocks with high growth potential. This was the second of three presentations Chemaphor will make as part of the 18 month, Richmond Media Investor Exposure Program. Chemaphor plans to implement several additional programs to increase communication and awareness with investors and the capital markets. Since announcing Chemaphor's collaboration with the Richmond Club, average daily volume of trading in Chemaphor shares has increased approximately 250% from the same period last year. Dr. Burton commented, "Chemaphor created Avivagen to commercialize the animal health opportunities presented by Chemaphor's unique, proprietary OxC-beta technology. Now that the first commercial OxC-beta product, Oximunol(TM) Chewables for dogs is on the Canadian market and being well received by consumers, we have begun making a concerted effort to grow awareness among investors and pet owners alike with events such as the Richmond Club webinar. This is an important forum for reaching a diverse group of experienced investors, brokers and analysts to showcase Chemaphor's wider opportunities, including the potential global use of OxC-beta as an alternative to the widespread, controversial use of antibiotics in animal food production."
The Webinar presentation can be found at the following link:
http://www.richmondclub.com/Luncheon Videos/ChemaphorOct2611/index.html
About Chemaphor
Chemaphor, a wellness company, is developing and delivering products from its unique, proprietary OxC-beta technology to assist in optimizing health and daily quality of life in animals and humans. Chemaphor has commercialized its first product for the companion animal market, Oximunol(TM) Chewables for dogs, and is advancing product candidates in the food animal market and for potential human applications. More information can be found at www.chemaphor.com.
About Avivagen
Avivagen Animal Health Inc., a wholly-owned subsidiary of Chemaphor, is a Canadian company dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials. More information can be found at www.avivagen.com.
About Richmond Media
The Richmond Media is celebrating its 11th year of helping its members profit from the Richmond Media Orphan Lift(TM). Members receive information about stocks that are selected for inclusion in the Richmond Club Index, which has dramatically out-performed the Dow, S&P and the TSX Venture Exchange. To be selected, a stock must have high growth potential and be undervalued as a result of being under-noticed. These stocks tend to rise to their fair market value as a result of an 18-month Richmond Media investor exposure program which provides these worthy stocks with investor exposure through: internet exposure, direct mailings and Richmond Media luncheon events. Richmond members are brokers, fund managers, analysts and members of the media.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
###
For more information:
David HankinsonGraham Burton, PhD
CEO, Chemaphor Inc.President and Co-Founder, Chemaphor Inc.
Phone: 902-825-9270Phone: 613-990-0969
[email protected]@chemaphor.com
Investor Relations:Media Group:
Evolution Group Inc.McCormick Global Communications Sylvain ArchambaultKaren Sample 514-448-4887 / Toll free: 866-703-4887519-475-6378 [email protected] [email protected]
www.evolutiongrp.com www.mccormickglobal.com